|
2023 Conference Publication Efficacy of immune checkpoint inhibitors (ICIs) in advanced mucosal melanoma (MM): A systematic review and metaanalysisPham, J. P., Hurwitz, J., Cosman, R., Goldinger, S. M., Sim, H. W., Dummer, R. and Joshua, A. M. (2023). Efficacy of immune checkpoint inhibitors (ICIs) in advanced mucosal melanoma (MM): A systematic review and metaanalysis. Congress of the European-Society-for-Medical-Oncology (ESMO), Madrid Spain, Oct 20-24, 2023. AMSTERDAM: ELSEVIER. doi: 10.1016/j.annonc.2023.09.2261 |
|
2018 Conference Publication The utility of chemotherapy after immunotherapy failure in metastatic melanoma: A multicenter case seriesGoldinger, Simone M., Lo, Serigne, Hassel, Jessica Cecile, Forschner, Andrea, McKean, Meredith Ann, Zimmer, Lisa, Khoo, Chloe Chia Hoey, Dummer, Reinhard, Eroglu, Zeynep, Buchbinder, Elizabeth Iannotti, Ascierto, Paolo Antonio, Gutzmer, Ralf, Rozeman, Elisa A., Hoeller, Christoph, Johnson, Douglas Buckner, Gesierich, Anja, Kolblinger, Peter, Benannoune, Naima, Cohen, Justine Vanessa and Menzies, Alexander M. (2018). The utility of chemotherapy after immunotherapy failure in metastatic melanoma: A multicenter case series. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. doi: 10.1200/JCO.2018.36.15_suppl.e21588 |
|
2017 Conference Publication Immunotherapy in patients with concurrent solid organ transplant, HIV, and Hepatitis B and CRai, R., Ezeoke, O. M., McQuade, J. L., Zimmer, L., Koo, C., Park, J. J., Ardolino, L., Yip, D., Goldinger, S., Cohen, J. V., Millward, M., Atkinson, V., Kane, A. Y., Ascierto, P. A., Garbe, C., Gutzmer, R., Johnson, D. B., Hellman, M. D., Long, G. V. and Menzies, A. M. (2017). Immunotherapy in patients with concurrent solid organ transplant, HIV, and Hepatitis B and C. 42nd European-Society-for-Medical-Oncology Congress (ESMO), Madrid Spain, Sep 08-12, 2017. OXFORD: OXFORD UNIV PRESS. |
|
2017 Conference Publication Melanoma patients treated with Encorafenib show less hyperproliferative keratinocytic cutaneous adverse events and more intense inflammatory palmoplantar erythrodysesthesia compared to other BRAF inhibitorsGraf, N., Goldinger, S., Galliker, N., Conrad, S. and Dummer, R. (2017). Melanoma patients treated with Encorafenib show less hyperproliferative keratinocytic cutaneous adverse events and more intense inflammatory palmoplantar erythrodysesthesia compared to other BRAF inhibitors. HOBOKEN: WILEY. |
|
2017 Conference Publication The peripheral blood TCR repertoire might facilitate patient stratification for immune checkpoint blockade inhibition in metastatic melanomaSchindler, S., Courtier, A., Jaberg-Bentele, N., Goldinger, S., Manuel, M., Perez, S., Mouret, J. -F., Nguyen-Kim, T. D. L., Raaijmakers, M., Kvistborg, P., Pasqua, N., Haanen, J., Dummer, R. and Levesque, M. (2017). The peripheral blood TCR repertoire might facilitate patient stratification for immune checkpoint blockade inhibition in metastatic melanoma. HOBOKEN: WILEY. |
|
2017 Conference Publication Sarcoid-like reactions under modern melanoma treatmentDimitriou, F., Frauchiger, A., Goldinger, S. M., Braun, R., Mangana, J. and Dummer, R. (2017). Sarcoid-like reactions under modern melanoma treatment. HOBOKEN: WILEY. |
|
2017 Conference Publication Thin melanoma in Swiss Patients: A clinicopathological comparisonKaufmann, C., Mangana, J., Cheng, P., Ramelyte, E., Goldinger, S. M., Levesque, M. P. and Dummer, R. (2017). Thin melanoma in Swiss Patients: A clinicopathological comparison. HOBOKEN: WILEY. |
|
2017 Conference Publication Hyperproliferative keratinocytic cutaneous adverse events and inflammatory palmoplantar erythrodysesthesia in melanoma patients treated with encorafenib compared to other BRAF inhibitorsGoldinger, Simone M., Graf, Natalie P., Galliker, Nadja, Conrad, Samuel and Dummer, Reinhard (2017). Hyperproliferative keratinocytic cutaneous adverse events and inflammatory palmoplantar erythrodysesthesia in melanoma patients treated with encorafenib compared to other BRAF inhibitors. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago Il, Jun 02-06, 2017. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. doi: 10.1200/JCO.2017.35.15_suppl.9590 |
|
2017 Conference Publication Re-challenge with BRAF-directed treatment: A multi-institutional retrospective studyValpione, Sara, Carlino, Matteo S., Mangana, Joanna, Mooradian, Meghan, McArthur, Grant A., Schadendorf, Dirk, Hauschild, Axel, Long, Georgina V., Arance, Ana M., Ascierto, Paolo Antonio, Maio, Michele, De Rosa, Francesco, Larkin, James M. G., Park, John J., Goldinger, Simone M., Flaherty, Keith, Xu, Wen, Livingstone, Elisabeth, Weichenthal, Michael and Lorigan, Paul (2017). Re-challenge with BRAF-directed treatment: A multi-institutional retrospective study. 53rd Annual Clinical Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago Il, Jun 02-07, 2017. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. doi: 10.1200/JCO.2017.35.15_suppl.9512 |
|
2017 Conference Publication Incidence, features and management of radionecrosis (RN) in melanoma patients (pts) treated with cerebral radiotherapy (RT) and anti-PD-1 antibodies (PD1)da Silva, Ines Esteves Domingues Pires, Johnpulle, Romany Anne Nilanthi, Banks, Patricia Diana, Grass, G. Daniel, Smith, Jess Louise, Everett, Ashlyn S., Goldinger, Simone M., -Thomson, Rachel Roberts, Millward, Michael, Glitza, Isabella Claudia, Haydu, Lauren Elaine, Atkinson, Victoria, Wang, Tim, Eroglu, Zeynep, Conry, Robert Martin, Shackleton, Mark J., Hong, Angela, Long, Georgina V., Johnson, Douglas Buckner and Menzies, Alexander M. (2017). Incidence, features and management of radionecrosis (RN) in melanoma patients (pts) treated with cerebral radiotherapy (RT) and anti-PD-1 antibodies (PD1). 53rd Annual Clinical Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago Il, Jun 02-07, 2017. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. doi: 10.1200/JCO.2017.35.15_suppl.9513 |
|
2016 Conference Publication Systemic treatment influences on immune accessibility of melanoma: A retrospective histopathological investigationKrahenbuhl, L., Goldinger, S. M., Kerl, K., Kempf, W., Chevolet, I., Brochez, L., Cheng, P., Mangana, J., Levesque, M. P. and Dummer, R. (2016). Systemic treatment influences on immune accessibility of melanoma: A retrospective histopathological investigation. OXFORD: OXFORD UNIV PRESS. doi: 10.1093/annonc/mdw379.28 |
|
2016 Conference Publication A phase I, open-label study of pasireotide in patients with BRAF-and NRAS-wild type, unresectable and or metastatic melanomaDummer, R., Michielin, O. A., Nageli, M., Goldinger, S. M., Campigotto, F., Kriemler-Krahn, U., Schmid, H., Pedroncelli, A., Micaletto, S. and Schadendorf, D. (2016). A phase I, open-label study of pasireotide in patients with BRAF-and NRAS-wild type, unresectable and or metastatic melanoma. OXFORD: OXFORD UNIV PRESS. doi: 10.1093/annonc/mdw379.43 |
|
2016 Conference Publication Does the distribution pattern of brain metastases during BRAF inhibitor therapy reflect the phenotype switch?Haueis, S., Kranzlin, P., Cheng, P., Mangana, J., Dummer, R. and Goldinger, S. (2016). Does the distribution pattern of brain metastases during BRAF inhibitor therapy reflect the phenotype switch?. HOBOKEN: WILEY-BLACKWELL. |
|
2016 Conference Publication Does the distribution pattern of brain metastases during BRAF inhibitor therapy reflect the phenotype switch?Haueis, S., Kranzlin, P., Cheng, P. F., Mangana, J., Dummer, R. and Goldinger, S. M. (2016). Does the distribution pattern of brain metastases during BRAF inhibitor therapy reflect the phenotype switch?. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. |
|
2016 Conference Publication An exploratory study investigating the metabolic activity and local cytokine profile in melanoma patients treated with pazopanib and paclitaxelThurneysen, S., Cheng, P. F., Nagel, H. W., Kunz, M., Jaberg-Bentele, N., Naegeli, M., Guenova-Hotzenecker, E., Goldinger, S., Mangana, J., Levesque, M. P. and Dummer, R. (2016). An exploratory study investigating the metabolic activity and local cytokine profile in melanoma patients treated with pazopanib and paclitaxel. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. |
|
2016 Conference Publication The value of PET/CT patterns in response prediction of metastasized melanoma treated with ipilimumabUrosevic-Maiwald, M., Goldinger, S. M., Sommerauer, M., Dummer, R. and Schaefer, N. G. (2016). The value of PET/CT patterns in response prediction of metastasized melanoma treated with ipilimumab. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. |
|
2016 Conference Publication Safety and anti-tumor activity of Pasireotide in patients with BRAF- and NRAS-wild type, unresectable and or metastatic melanoma: a phase I, open-label, single-arm studySchadendorf, D., Michielin, O., Nageli, M., Goldinger, S. M., Campigotto, F., Kriemler-Krahn, U., Schmid, H. A., Pedroncelli, A. M., Micaletto, S. and Dummer, R. (2016). Safety and anti-tumor activity of Pasireotide in patients with BRAF- and NRAS-wild type, unresectable and or metastatic melanoma: a phase I, open-label, single-arm study. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. |
|
2016 Conference Publication Multi-center real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in SwitzerlandMangana, J., Amann, V. C., Goldinger, S. M., Kaufmann, C., Frauchiger, A. L., Cheng, P., Stoegner, V., Held, U., Von Moos, R., Romano, E., Michielin, O., Braun, R., Levesque, M. P. and Dummer, R. (2016). Multi-center real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. |
|
2016 Conference Publication Correlation between metastatic site and response to anti-Programmed Death-1 (PD-1) agents in melanomaGoldinger, Simone M., Tsai, Katy K., Tumeh, Paul, Hamid, Omid, Nosrati, Adi, Loo, Kimberly, Grimes, Barbara, Algazi, Alain Patrick, Levesque, Mitchell P., Dummer, Reinhard and Daud, Adil (2016). Correlation between metastatic site and response to anti-Programmed Death-1 (PD-1) agents in melanoma. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago Il, Jun 03-07, 2016. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. doi: 10.1200/JCO.2016.34.15_suppl.9549 |
|
2016 Conference Publication Derivation and validation of a prediction scale for response to PD-1 monotherapyNosrati, Adi, Goldinger, Simone M., Tsai, Katy K., Loo, Kimberly, Tumeh, Paul, Hamid, Omid, Algazi, Alain Patrick, Levesque, Mitchell P., Dummer, Reinhard and Daud, Adil (2016). Derivation and validation of a prediction scale for response to PD-1 monotherapy. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago Il, Jun 03-07, 2016. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. doi: 10.1200/JCO.2016.34.15_suppl.9514 |
